OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus
Laurenz T. Fischer, Daniel A. Hochfellner, Lisa Knoll, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 14
Laurenz T. Fischer, Daniel A. Hochfellner, Lisa Knoll, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 14
Showing 14 citing articles:
PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis
Xing Wang, Dingke Wen, Yuqi Chen, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 52
Xing Wang, Dingke Wen, Yuqi Chen, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 52
First clinical experiences with inclisiran in a real-world setting
Janneke W.C.M. Mulder, Annette M.H. Galema‐Boers, Jeanine E. Roeters van Lennep
Journal of clinical lipidology (2023) Vol. 17, Iss. 6, pp. 818-827
Open Access | Times Cited: 20
Janneke W.C.M. Mulder, Annette M.H. Galema‐Boers, Jeanine E. Roeters van Lennep
Journal of clinical lipidology (2023) Vol. 17, Iss. 6, pp. 818-827
Open Access | Times Cited: 20
Eficacia y seguridad de los inhibidores de la PCSK9 en la vida real
Antón González-Guerrero, Eugenia Navarrete-Rouco, David Benaiges, et al.
Clínica e Investigación en Arteriosclerosis (2025), pp. 500755-500755
Closed Access
Antón González-Guerrero, Eugenia Navarrete-Rouco, David Benaiges, et al.
Clínica e Investigación en Arteriosclerosis (2025), pp. 500755-500755
Closed Access
Effects of PCSK9 inhibitors on cancer, diabetes, and cardiovascular diseases
Mojgan Nejabat, Farzin Hadizadeh, Wael Almahmeed, et al.
Drug Discovery Today (2025), pp. 104316-104316
Closed Access
Mojgan Nejabat, Farzin Hadizadeh, Wael Almahmeed, et al.
Drug Discovery Today (2025), pp. 104316-104316
Closed Access
Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial
Andrei C. Spósito, Íkaro Breder, Joaquim Barreto, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 14
Andrei C. Spósito, Íkaro Breder, Joaquim Barreto, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 14
Safety, adherence and efficacy of PCSK9 inhibitors: a retrospective real-world study
Bee Ling Kelly Chng, Wei Min Paul Heng, Yu Ming Soon, et al.
Proceedings of Singapore Healthcare (2022) Vol. 31
Closed Access | Times Cited: 9
Bee Ling Kelly Chng, Wei Min Paul Heng, Yu Ming Soon, et al.
Proceedings of Singapore Healthcare (2022) Vol. 31
Closed Access | Times Cited: 9
Morphologies and composition changes in nonculprit subclinical atherosclerosis in diabetic versus nondiabetic patients with acute coronary syndrome who underwent long-term statin therapy
Pei-na Meng, Jia-cong Nong, Yi Xu, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Pei-na Meng, Jia-cong Nong, Yi Xu, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Evolving ANGPTL-based lipid-lowering strategies and beyond
Dominic S. Ng
Current Opinion in Lipidology (2021) Vol. 32, Iss. 4, pp. 271-272
Closed Access | Times Cited: 8
Dominic S. Ng
Current Opinion in Lipidology (2021) Vol. 32, Iss. 4, pp. 271-272
Closed Access | Times Cited: 8
PCSK9 Inhibitor Use and Outcomes Using Concomitant Lipid-Lowering Therapies in the Veterans Health Administration
Jessica Eloso, Asma Awad, Xinhua Zhao, et al.
American Journal of Medicine Open (2023) Vol. 9, pp. 100035-100035
Open Access | Times Cited: 2
Jessica Eloso, Asma Awad, Xinhua Zhao, et al.
American Journal of Medicine Open (2023) Vol. 9, pp. 100035-100035
Open Access | Times Cited: 2
Real-World Data on Comparison of Lipid-Lowering Effects between Alirocumab and Evolocumab in Patients with Hypercholesterolemia.
Dai-Yi Lin, Chia-Ling Tsai, Ya-Hui Chang, et al.
PubMed (2022) Vol. 38, Iss. 6, pp. 778-783
Closed Access | Times Cited: 3
Dai-Yi Lin, Chia-Ling Tsai, Ya-Hui Chang, et al.
PubMed (2022) Vol. 38, Iss. 6, pp. 778-783
Closed Access | Times Cited: 3
PCSK9 inhibitors in real life—Cardiometabolic risk management in dyslipidemic patients in Vienna
Moritz Ferch, Caroline Sert, Paul Fellinger, et al.
Wiener klinische Wochenschrift (2024)
Open Access
Moritz Ferch, Caroline Sert, Paul Fellinger, et al.
Wiener klinische Wochenschrift (2024)
Open Access
The Efficacy and Safety of Inclisiran for Low-Density Lipoprotein (LDL) in Patients With Atherosclerotic Cardiovascular Disease (ASCVD): A Systematic Review of Randomized Controlled Trials
Hyder Osman Mirghani, Basmah A. Albalawi, Mohammed S. Alshehri, et al.
Cureus (2024)
Open Access
Hyder Osman Mirghani, Basmah A. Albalawi, Mohammed S. Alshehri, et al.
Cureus (2024)
Open Access
PCSK9 inhibitors and treatment targets: an audit-based evaluation of a specialist lipid clinic
Anirudh Suresh, Aikaterini Theodoraki, Emily Ward, et al.
British Journal of Diabetes (2022) Vol. 22, Iss. 1, pp. 30-35
Open Access | Times Cited: 1
Anirudh Suresh, Aikaterini Theodoraki, Emily Ward, et al.
British Journal of Diabetes (2022) Vol. 22, Iss. 1, pp. 30-35
Open Access | Times Cited: 1
The ‘real world’ is relative—biased
Nicolle Kränkel
European Journal of Preventive Cardiology (2021) Vol. 29, Iss. 9, pp. 1331-1333
Open Access
Nicolle Kränkel
European Journal of Preventive Cardiology (2021) Vol. 29, Iss. 9, pp. 1331-1333
Open Access
